Abbott Molecular, Inc. recalls Alinity m Resp-4-Plex AMP Kit and 1 more
- Published
- 21 May 2025
- Units affected
- 2 products
- Agency
- FDA
- Country
- United States
The hazard
There were reports of an increase in reactive negative controls and false positive results.
Classification: Class II — this product may cause temporary or medically reversible health problems; the chance of serious harm is remote.
What to do
Contact your doctor, clinic or the device maker to find out if your device is affected and what to do next. Do not stop using a life-supporting device without medical advice.
- Check the model and lot or serial number on the device label.
- Speak to your doctor or the clinic that supplied the device before stopping use.
Product details
Alinity m Resp-4-Plex AMP Kit, List Number 09N79-096, a multiplex real-time reverse transcription (RT) polymerase chain reaction (PCR) test intended for the simultaneous qualitative detection and differentiation of RNA from SARS-CoV-2, influenza A virus (flu A), influenza B virus (flu B), and/or Respiratory Syncytial Virus (RSV) in anterior nasal or nasopharyngeal swab specimens collected by a healthcare provider (HCP), or in anterior nasal swab specimens that are self-collected at a healthcare location, from individuals suspected by their HCP of respiratory viral infection consistent with COVID-19.
Alinity m Resp-4-Plex Amplification (AMP) Kit (CE), List Number 09N79-090, a multiplex real-time reverse transcription (RT) polymerase chain reaction (PCR) test intended for the qualitative detection and differentiation of RNA from influenza A virus (flu A), influenza B virus (flu B), Respiratory Syncytial Virus (RSV), and SARS-CoV-2 in nasopharyngeal (NP) swab specimens collected by a healthcare provider, from individuals with signs and symptoms of respiratory tract infection
- Brand / company
- Abbott Molecular, Inc.
- Codes / lots
- UDI-DI: 00884929049390; Lot Number: 409384 | UDI-DI: 00884999049338; Lot Numbers: 409383 410627 411921
- Distribution
- Worldwide - US Nationwide distribution.
- Recall status
- Ongoing
Source: U.S. Food and Drug Administration, published 21 May 2025. CheckMyRecalls reproduces the official notice in summary; always confirm the details with the original notice.